Beyhan Zaim appointed Vice President Commercial Development & Alzheimer's Disease Global Lead, Neurology Business Group at Eisai Inc.

WOODCLIFF LAKE, N.J., April 11, 2016 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Beyhan Zaim as Vice President Commercial Development & Alzheimer's Disease Global Lead, Neurology Business Group.

Ms. Zaim will lead Eisai's Neurology Commercial Development team in creating and driving commercial strategies for pipeline assets and late stage compounds approaching the commercialization stage. As the Global Lead for Alzheimer's Disease (AD), she will develop strategies and head the collaborative efforts of internal and external stakeholders to progress the development of existing as well as potential future AD assets. In addition to her functional responsibilities, she has been appointed as a standing member of the Executive Committee for the Neurology Business Group.

"With her deep expertise in the commercial development of in-line and pipeline compounds, and extensive knowledge of Alzheimer's disease and other neurodegenerative disease states, Beyhan is a tremendous addition to Eisai," said Ivan Cheung, Chairman and CEO of Eisai Inc. and President of the Neurology Business Group. "We are confident that she will help drive the global growth of Eisai's products, as well as work to ensure that Eisai remains a leader in the AD marketplace."   

Ms. Zaim joins Eisai from Pfizer, where she held diverse global positions encompassing business development, global marketing, strategic planning, and all aspects of commercial development. She also held a number of international assignments, including Asia Business Development Director based in Hong Kong and Country Manager of Thailand. In her most recent roles, she served as Vice President of External Opportunities and New Business; Vice President of Commercial Development Primary Care Business Unit; and Vice President, Medicine Team Leader.

Ms. Zaim holds a Master of Business Administration from Columbia Business School, the business school of Columbia University located in Manhattan, New York City. She earned her Bachelor of Science degree from the Rutgers School of Pharmacy.

Eisai Inc.
At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and neurology. To learn more about Eisai Inc., please visit us at www.eisai.com/US.

Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey and Pennsylvania, as well as a global demand chain organization that includes facilities in Maryland and North Carolina. Eisai's global areas of R&D focus include neuroscience; oncology; metabolic disorders; vascular, inflammatory and immunological reaction; and antibody-based programs.

Eisai Co. Ltd.
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With over 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including oncology and neurology. For more information about Eisai Co., Ltd., please visit www.eisai.com.

SOURCE Eisai Inc.